Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts VIR Hot Sheet
Join SI Premium – FREE
Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($1.56), $0.51 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.38 million versus the consensus estimate of $5.54 million.
For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Astera Labs, Inc. (ALAB) Tops Q3 EPS by 13c, Beats on Revenue
- Claros Mortgage Trust, Inc. (CMTG) Tops Q3 EPS by 31c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
